Insider Transactions in Q2 2021 at Royalty Pharma PLC (RPRX)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
William E Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
871
+11.66%
|
$37,453
$43.04 P/Share
|
|
Jun 30
2021
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
871
+3.85%
|
$37,453
$43.04 P/Share
|
|
Jun 30
2021
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
871
+5.17%
|
$37,453
$43.04 P/Share
|
|
Jun 29
2021
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Indirect |
481,000
-6.12%
|
$19,721,000
$41.63 P/Share
|
|
Jun 28
2021
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Indirect |
167,448
-4.08%
|
$7,032,816
$42.11 P/Share
|
|
Jun 25
2021
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+23.03%
|
-
|
|
Jun 25
2021
|
Gregory Norden Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+10.21%
|
-
|
|
Jun 25
2021
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+27.47%
|
-
|
|
Jun 25
2021
|
William E Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+50.0%
|
-
|
|
Jun 25
2021
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+21.5%
|
-
|
|
Jun 25
2021
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Indirect |
666,464
-13.36%
|
$27,991,488
$42.75 P/Share
|
|
Jun 25
2021
|
Errol B Desouza Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+10.21%
|
-
|
|
Jun 25
2021
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+20.03%
|
-
|
|
Jun 10
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
70,000
-3.82%
|
$3,220,000
$46.48 P/Share
|
|
Jun 08
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
50,000
-3.79%
|
$2,300,000
$46.43 P/Share
|
|
Jun 08
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
70,000
-3.68%
|
$3,220,000
$46.48 P/Share
|
|
Jun 07
2021
|
Rory B Riggs Director |
BUY
Open market or private sale
|
Indirect |
273,650
+11.62%
|
$12,314,250
$45.26 P/Share
|
|
Jun 07
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
50,000
-1.83%
|
$2,300,000
$46.79 P/Share
|
|
Jun 07
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
122,500
-3.15%
|
$5,635,000
$46.34 P/Share
|
|
Jun 07
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
16,568
-100.0%
|
$778,696
$47.02 P/Share
|
|
Jun 04
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
100,000
-6.8%
|
$4,400,000
$44.6 P/Share
|
|
Jun 04
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
60,000
-3.79%
|
$2,640,000
$44.78 P/Share
|
|
Jun 04
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
16,566
-50.0%
|
$745,470
$45.13 P/Share
|
|
Jun 02
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
62,500
-3.13%
|
$2,625,000
$42.11 P/Share
|
|
Jun 02
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
50,000
-3.29%
|
$2,100,000
$42.13 P/Share
|
|
Jun 02
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
14,566
-30.54%
|
$597,206
$41.52 P/Share
|
|
May 21
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
100
-0.21%
|
$4,100
$41.0 P/Share
|
|
May 20
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
1,900
-3.82%
|
$77,900
$41.08 P/Share
|
|
May 07
2021
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Indirect |
2,355,190
+50.0%
|
-
|
|
May 07
2021
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Direct |
679,760
+50.0%
|
-
|
|
May 07
2021
|
George W. Lloyd EVP, Investments & CLO |
BUY
Conversion of derivative security
|
Indirect |
1,875,860
+47.74%
|
-
|
|
May 07
2021
|
Terrance P. Coyne EVP & CFO |
BUY
Conversion of derivative security
|
Indirect |
1,000,000
+50.0%
|
-
|
|
May 07
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
BUY
Conversion of derivative security
|
Indirect |
1,320,800
+46.48%
|
-
|
|
May 07
2021
|
Marshall Urist EVP, Research & Investments |
BUY
Conversion of derivative security
|
Direct |
49,700
+50.0%
|
-
|
|
May 07
2021
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
2,325,000
+50.0%
|
-
|
|
Apr 14
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
55,714
-21.79%
|
$2,339,988
$42.1 P/Share
|
|
Apr 14
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
69,822
-21.81%
|
$2,932,524
$42.13 P/Share
|
|
Apr 12
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
359
-0.14%
|
$15,078
$42.32 P/Share
|
|
Apr 12
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
449
-0.14%
|
$18,858
$42.32 P/Share
|